干扰素治疗慢性活动性乙型肝炎146例临床观察

Observation of curative effect of interferon-αfor chronic hepatitis B

目的评价干扰素(IFN-α)治疗慢性活动性乙型肝炎(chronic active hepatitis B)的近、远期疗效和安全性。方法选取慢性活动性乙型肝炎患者146例,ALT升高两倍以上,HBV-DNA>10E5copy/mol及HBeAg阳性的CHB患者随机分为两组。治疗组采用干扰素(IFN-α)加常规护肝降酶药(古拉定,甘利欣,丹参)治疗,对照组仅采用单一常规护肝降酶药(甘利欣,古拉定,丹参静脉滴注3个月续以口服护肝降酶药物)治疗,疗程均为12个月,观察患者症状、肝功能及乙肝病毒复制指标的治疗效果。结果治疗组HBV-DNA转阴64例(66.36%),对照组HBV-DNA转阴18例(18.84%),近、远期疗效均有显著性差异。但对持续降低肝酶(ALT)的复常率无明显差异。结论干扰素(IFN-α)抗病毒效果好,是目前治疗慢性活动性乙型肝炎安全有效的方法之一。

Objective：To study the long-term,short-term curative efficacy and safety of interferon-αin HbeAg positive chronic hepatitis B patient.Methods： One hundred and forty-six patients with hepatitis B were randomized into 2 groups： 73（treatment group） were assigned to receive interferon-αplus Huganjiangmei（HGJMK） medicine（diammonium glycyrrhizinate,Salvia Miltiorrhiza Injection.ect） for 12 months,and 73（control group） to receive Huganjiangmei（HGJMK）medicine（diammonium glycyrrhizinate,Salvia Miltiorrhiza Injection.ect）alone for 12 months. Results： Proportions of HbeAg seroconversion in the treatment group and the control group were 65.75% and 46.58 % respectively （P 〈0.05） and proportions of HBV-DNA seroconversion were 66.36% and 18.84% respectively （ P 〈 0.05）. Conclusion： Interferon is effective in HBeAg positive chronic hepatitis B patients,which can inhibit the HBV-DNA replication and has good effect on resisting fibrosis action.